Arrowhead Pharmaceuticals reports FY 2026 loss as REDEMPLO sales begin and SHTG launch planned for 2027
Arrowhead Pharmaceuticals announced fiscal 2026 results, posting a net loss of $724.2 million, or $5.11 per share, on revenue of $450.8 million. The loss was driven by a $215 million priority‑review voucher expense and the absence of $829 million of collaboration revenue recorded in the prior year. REDEMPLO generated $6.6 million of product revenue, and the company filed an sNDA for severe hypertriglyceridemia (SHTG) with a target U.S. launch in the second quarter of 2027, estimating a $3‑$4 billion annual market opportunity.
Why it matters
The earnings release shows a sharp earnings swing from a $1.6 million loss a year earlier, highlighting the financial impact of one‑time items and reduced collaboration cash. Management’s focus on REDEMPLO uptake and a planned SHTG launch signals potential future revenue growth, which investors will weigh against the current loss.
Key facts
- 1Net loss for FY 2026 was $724.2 million, or $5.11 per share. finance.biggo.com
- 2Total revenue for FY 2026 was $450.8 million, down 45.6% from $829.4 million in FY 2025. finance.biggo.com
- 3REDEMPLO generated $6.6 million of net product revenue in FY 2026. finance.biggo.com
- 4A $215 million expense for a priority review voucher was recorded in FY 2026. finance.biggo.com
- 5The company filed a supplemental NDA for severe hypertriglyceridemia and targets a U.S. launch in Q2 2027. finance.biggo.com
- 6Management estimates the SHTG indication could reach $3 billion‑$4 billion in annual U.S. sales. finance.biggo.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.